Ann Pharmacol Pharm | Volume 9, Issue 1 | Review Article | Open Access

Application of Raloxifene in Breast Cancer and Its Effect on Other Tissues: A Review Study

Mirzapur P^*, Khazaei MR, Rezakhani L and Khazaei M^*

Fertility and Infertility Research Center, Kermanshah University of Medical Sciences, Iran

^*Correspondance to: Pegah Mirzapur 

Abstract

As a leading cause of mortality among women, breast cancer can be targeted by Estrogen Receptors (ERs), which are in turn affected by SERMs compounds. Various clinical trials have approved the effect of Raloxifene (RAL) on reducing the risk of Breast Cancer (BC) and osteoporosis in postmenopausal women. Due to its pivotal role in the health of women with a high risk of BC, there is currently a strong demand to use RAL as an alternative hormonal treatment capable of reducing the risk of invasive BC. RAL has effects on most tissues, but its use is contingent upon specific conditions.

Keywords:

SERM; Raloxifene; Cancer; Estrogen receptor; Chemoprevention

Citation:

Mirzapur P, Khazaei MR, Rezakhani L, Khazaei M. Application of Raloxifene in Breast Cancer and Its Effect on Other Tissues: A Review Study. Ann Pharmacol Pharm. 2024; 9(1): 1213..